Yeomans Consulting Group, Inc. Alnylam Pharmaceuticals, Inc. Transaction History
Yeomans Consulting Group, Inc.
- $290 Billion
- Q3 2025
A detailed history of Yeomans Consulting Group, Inc. transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, Yeomans Consulting Group, Inc. holds 984 shares of ALNY stock, worth $466,416. This represents 0.16% of its overall portfolio holdings.
Number of Shares
984Holding current value
$466,416% of portfolio
0.16%Shares
1 transactions
Others Institutions Holding ALNY
# of Institutions
780Shares Held
115MCall Options Held
584KPut Options Held
661K-
Capital World Investors Los Angeles, CA16.8MShares$7.97 Billion0.83% of portfolio
-
Vanguard Group Inc Valley Forge, PA13.3MShares$6.3 Billion0.07% of portfolio
-
Black Rock Inc. New York, NY9.55MShares$4.53 Billion0.05% of portfolio
-
Capital Research Global Investors Los Angeles, CA7.19MShares$3.41 Billion0.49% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD4.28MShares$2.03 Billion0.88% of portfolio
About ALNYLAM PHARMACEUTICALS, INC.
- Ticker ALNY
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 123,028,000
- Market Cap $58.3B
- Description
- Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...